ALESSANDRA BROWN: Open Payments
NPI 1063106052 · WINSTON SALEM, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$989 in 46 payments from 12 companies in 2025. Trend: 2023 $0 · 2024 $15 · 2025 $989
Food & beverage: $989
| Company | Payments | Amount |
|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $197 |
| GlaxoSmithKline, LLC. | 10 | $171 |
| Regeneron Healthcare Solutions, Inc. | 8 | $137 |
| Viatris Specialty LLC | 4 | $87 |
| GENZYME CORPORATION | 4 | $85 |
| Verona Pharma, Inc. | 3 | $69 |
| United Therapeutics Corporation | 3 | $69 |
| AstraZeneca Pharmaceuticals LP | 3 | $51 |
| HARMONY BIOSCIENCES LLC | 2 | $47 |
| Merck Sharp & Dohme LLC | 2 | $34 |
Products named: DUPIXENT, OFEV, NUCALA, YUPELRI, Ohtuvayre, Tyvaso, TRELEGY ELLIPTA, WAKIX.
Industry payments across NC — which companies pay providers there.
